36 Result(s)

Article

Targeting MYC in multiple myeloma

Multiple myeloma (MM) is a plasma cell tumor marked by clonal evolution and preceded by a premalignant stage, which progresses via molecular pathway deregulation, including MYC activation. This activation rela...

K. K. Jovanović, C. Roche-Lestienne, I. M. Ghobrial, T. Facon, B. Quesnel… in Leukemia (2018)

Article

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

Deletions of the 1p region appear as a pejorative prognostic factor in multiple myeloma patients (especially 1p22 and 1p32 deletions) but there is a lack of data on the real impact of 1p abnormalities on an im...

B Hebraud, X Leleu, V Lauwers-Cances, M Roussel, D Caillot, G Marit, L Karlin… in Leukemia (2014)

Article

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

X Leleu, G Fouquet, B Hebraud, M Roussel, D Caillot, M L Chrétien, B Arnulf… in Leukemia (2013)

Article

Minor clone provides a reservoir for relapse in multiple myeloma

Recent studies have provided direct evidence for genetic variegation in subclones for various cancer types. However, little is known about subclonal evolutionary processes according to treatment and subsequent...

F Magrangeas, H Avet-Loiseau, W Gouraud, L Lodé, O Decaux, P Godmer, L Garderet… in Leukemia (2013)

Article

Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens

S Manier, M Barthelemy, G Fouquet, C Prod’homme, E Le Ray, P Samarcq, M P Noel… in Leukemia (2012)

Article

Renouveau des traitements d’entretien dans le myélome multiple : place des immunomodulateurs (IMiDs)

The use of maintenance therapy demonstrated benefits only since the 1980s, since the era of targeted novel agents, especially immunomodulatory drugs (IMiDs) in multiple myeloma. Several phase 3 randomized clin...

S. Manier, E. Boyle, J. Gauthier, C. Bories, T. Facon, X. Leleu in Oncologie (2011)

Article

Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma

P Moreau, F Cavallo, X Leleu, C Hulin, M Amiot, G Descamps, T Facon… in Leukemia (2011)

Article

Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma

Thalidomide has received approval from the European Agency for the Evaluation of Medicinal Products for the treatment of newly diagnosed multiple myeloma (MM) patients older than 65 years or ineligible for tra...

A. Palumbo, F. Davies, M. Kropff, J. Bladé, M. Delforge… in Annals of Hematology (2010)

Article

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Nilotinib is a highly selective Bcr–Abl inhibitor approved for imatinib-resistant chronic myeloid leukemia (CML). Nilotinib and dasatinib, a multi-targeted kinase inhibitor also approved for second-line therap...

F J Giles, E Abruzzese, G Rosti, D-W Kim, R Bhatia, A Bosly, S Goldberg… in Leukemia (2010)

Article

Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005–01 trial

P Moreau, C Hulin, G Marit, D Caillot, T Facon, P Lenain, C Berthou, B Pégourié… in Leukemia (2010)

Article

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

Renal impairment is associated with poor prognosis in multiple myeloma (MM). This subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib vs hig...

J F San-Miguel, P G Richardson, P Sonneveld, M W Schuster, D Irwin… in Leukemia (2008)

Article

Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials

One hundred de novo multiple myeloma patients with t(4;14) treated with double intensive therapy according to IFM99 protocols were retrospectively analyzed. The median overall survival (OS) and event-free surviva...

P Moreau, M Attal, F Garban, C Hulin, T Facon, G Marit, M Michallet, C Doyen… in Leukemia (2007)

Article

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

In multiple myeloma, deletion of chromosome 13 (del(13)) is associated with poor prognosis regardless of treatment. This study analyzed the impact of del(13) status on response and survival following treatment...

S Jagannath, P G Richardson, P Sonneveld, M W Schuster, D Irwin, E A Stadtmauer… in Leukemia (2007)